Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 10, 2015, Pages 2854-2861

  Grau, S ^a,e   Luque, S ^a,f   Campillo, N ^b   Samso E ^a   Rodriguez U ^a   Garcia Bernedo C A ^a   Salas, E ^a   Sharma, R ^c   Hope, W W ^d   Roberts, J A ^d,f  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; MICAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN; LIPOPEPTIDE;

ADULT; AGED; ANTIFUNGAL ACTIVITY; APACHE; AREA UNDER THE CURVE; ARTICLE; CANDIDA PARAPSILOSIS; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PERITONEAL FLUID LEVEL; FEMALE; HUMAN; INVASIVE CANDIDIASIS; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PERITONEAL CAVITY; PERITONEAL FLUID; PERITONITIS; POSTOPERATIVE INFECTION; PROTEIN BINDING; SURGICAL PATIENT; VOLUME OF DISTRIBUTION; ASCITES FLUID; CANDIDIASIS; CRITICAL ILLNESS; DRUG MONITORING; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PLASMA; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ASCITIC FLUID; CANDIDIASIS; CRITICAL ILLNESS; DRUG MONITORING; ECHINOCANDINS; FEMALE; HUMANS; LIPOPEPTIDES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; PERITONITIS; PLASMA; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 84943738569     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv173     Document Type: Article

References (34)

1. Eckmann C, Dryden M, Montravers P et al. Antimicrobial treatment of 'complicated' intra-abdominal infections and the new IDSA guidelines: a commentary and an alternative European approach according to clinical definitions. Eur J Med Res 2011; 28; 16: 115-26.
2. Bassetti M, Marchetti M, Chakrabarti A et al. A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med 2013; 39: 2092-106.
3. Montravers P, Mira JP, Gangneux JP et al. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect 2011; 17: 1061-7.
4. Montravers P, Dupont H, Gauzit R et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006; 34: 646-52.
5. Sinnollareddy M, Peake SL, Roberts MS et al. Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. Int J Antimicrob Agents 2012; 39: 1-10.
6. Roberts JA, Paul SK, Akova M et al. DALI: defining antibiotic levels in intensive care unit patients: are current b-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 2014; 58: 1072-83.
7. Cornely OA, Bassetti M, Calandra T et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18: 19-37.
8. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-93.
9. Chiou CC, Mavrogiorgos N, Tillem E et al. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother 2001; 45: 3310-21.
10. WHO. Global Database on Body Mass Index. http://apps.who.int/bmi/index.jsp?introPage=intro_3.html.
11. Charlson M, Szatrowski TP, Peterson J et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245-51.
12. KnausWA, Draper EA, Wagner DP et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
13. Vincent JL, Moreno R, Takala J et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996; 22: 707-10.
14. Bosscha K, Reijnders K, Hulstaert PF et al. Prognostic scoring systems to predict outcome in peritonitis and intra-abdominal sepsis. Br J Surg 1997; 84: 1532-4.
15. León C, Ruiz-Santana S, Saavedra P et al. A bedside scoring system ('Candida score') for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34: 730-7.
16. Martens-Lobenhoffer J, Rupprecht V, Bode-Böger SM et al. Determination of micafungin and anidulafungin in human plasma: UVor mass spectrometric quantification? J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 2051-6.
17. Tatarinova T, Neely M, BartroffJ et al. Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and nonparametric Bayesian. J Pharmacokinet Pharmacodyn 2013; 40: 189-99.
18. Neely MN, van Guilder MG, Yamada WM et al. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 2012; 34: 467-76.
19. EUCAST. Micafungin and Candida spp. Rationale for the EUCAST Clinical Breakpoints, Version 1.0, 2013. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/Micafungin_rationale_document_1_0_final.pdf.
20. Andes D, Ambrose PG, Hammel JP et al. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. Antimicrob Agents Chemother 2011; 55: 2113-21.
21. Undre NA, Stevenson P, Kuse E et al. Pharmacokinetics of micafungin in adult patients with invasive candidiasis and candidemia. Open J Med Microbiol 2012; 2: 84-90.
22. Keirns J, Sawamoto T, Holum M et al. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults. Antimicrob Agents Chemother 2007; 51: 787-90.
23. Pea F, Righi E, Cojutti P et al. Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis. J Antimicrob Chemother 2014; 69: 2585-6.
24. Bozzette SA, Gordon RL, Yen A et al. Biliary concentrations of fluconazole in a patient with candidal cholecystitis: case report. Clin Infect Dis 1992; 15: 701-3.
25. Peterson LR, Kelty RH, Hall WH et al. Therapy of Candida peritonitis: penetration of amphotericin B into peritoneal fluid. Postgrad Med J 1978; 54: 340-2.
26. Muther RS, Bennett WM. Peritoneal clearance of amphotericin B and 5-fluorocytosine. West J Med 1980; 133: 157-60.
27. Van der Voort PH, Boerma EC, Yska JP. Serum and intraperitoneal levels of amphotericin B and flucytosine during intravenous treatment of critically ill patients with Candida peritonitis. J Antimicrob Chemother 2007; 59: 952-6.
28. Aguado JM, Hidalgo M, Rodríguez-Tudela JL. Successful treatment of Candida peritonitiswith fluconazole. J AntimicrobChemother 1994; 34: 847.
29. Weiler S, Bellmann-Weiler R, Dunzendorfer S et al. Levels of amphotericin B lipid formulations in ascites. J Antimicrob Chemother 2008; 62: 1163-4.
30. Blowey DL, Garg UC, Kearns GL et al. Peritoneal penetration of amphotericin B lipid complex and fluconazole in a pediatric patient with fungal peritonitis. Adv Perit Dial 1998; 14: 247-50.
31. Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev 2014; 27: 68-88.
32. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-27.
33. Hall RG, Swancutt MA, Meek C et al. Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths. Antimicrob Agents Chemother 2013; 57: 2259-64.
34. Mouton JW, Theuretzbacher U, Craig WA et al. Tissue concentrations: do we ever learn? J Antimicrob Chemother 2008; 61: 235-7.